Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

Home

CRIS

C

Curis, Inc. (CRIS)

NCM – Real Time Price. Currency in USD

0.56

-0.02 (-4.22%)

At close: Mar 27, 2026, 4:00 PM EDT

0.56

+0.00 (0.83%)

After-hours: Mar 27, 2026, 7:18 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript

Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript

Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript

Curis Provides Fourth Quarter 2025 Business Update

Curis Provides Fourth Quarter 2025 Business Update

Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.

Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026

Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026

LEXINGTON, Mass., March 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its fourth quarter 2025 financial and operating results on Thursday, March 19, 2026, at 4:00 p.m.

Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the closing of its previously announced private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the Company of approximately $20.2 million, in each case before placement agent fees and offering expenses.

Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

LEXINGTON, Mass., Jan. 7, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into a securities purchase agreement with new and existing healthcare-focused, high-quality institutional investors and certain insiders of the Company for a private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the Company of approximately $20.2 million, in each case before placement agent fees and offering expenses.

Curis Provides Updated Data from its Frontline AML Triplet Study

Curis Provides Updated Data from its Frontline AML Triplet Study

5 of 8 patients (62.5%) achieved Undetectable MRD (uMRD) LEXINGTON, Mass. , Dec. 9, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, yesterday provided updated clinical data from the ongoing frontline Acute Myeloid Leukemia (AML) triplet study (CA-4948-104) in a poster presentation at the 67th ASH Annual Meeting (ASH).

Curis to Present at Upcoming 30th Annual SNO Meeting

Curis to Present at Upcoming 30th Annual SNO Meeting

LEXINGTON, Mass. , Nov. 14, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that Curis will report emavusertib and BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) in three presentations and preclinical data on emavusertib in an oral presentation at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) on November 19-23: November 21, 2025 – 4:30 PM ET (11:30 AM HT) Format: Poster Presentation Presenter: Dr. Christian Grommes, Memorial Sloan Kettering Cancer Center, NY, NY Title: Analysis of Genetic Mutation Profile and CNS Pharmacokinetics in Relapsed/Refractory Primary CNS Lymphoma Patients Responding to Novel Emavusertib (IRAK4i) and BTKi Combination Format: Poster Presentation Presenter: Dr. Lakshmi Nayak, Dana-Farber Cancer Institute, Boston, MA Title: Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma Patients November 22, 2025 – 4:45 PM ET (11:45 AM HT) Format: Rapid Oral Presentation Presenter: Dr. Christian Grommes, Memorial Sloan Kettering Cancer Center, NY, NY Title: Analysis of Genetic Mutation Profile and CNS Pharmacokinetics in Relapsed/Refractory Primary CNS Lymphoma Patients Responding to Novel Emavusertib (IRAK4i) and BTKi Combination Format: Poster Presentation Presenter: Cecilia A.

Videos

No Data

There is no data to display

Press releases

Curis Provides Fourth Quarter 2025 Business Update

Curis Provides Fourth Quarter 2025 Business Update

Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.

Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

09.01.2026

Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the closing of its previously announced private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the Company of approximately $20.2 million, in each case before placement agent fees and offering expenses.

Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

LEXINGTON, Mass., Jan. 7, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into a securities purchase agreement with new and existing healthcare-focused, high-quality institutional investors and certain insiders of the Company for a private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the Company of approximately $20.2 million, in each case before placement agent fees and offering expenses.

Curis Provides Updated Data from its Frontline AML Triplet Study

Curis Provides Updated Data from its Frontline AML Triplet Study

5 of 8 patients (62.5%) achieved Undetectable MRD (uMRD) LEXINGTON, Mass. , Dec. 9, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, yesterday provided updated clinical data from the ongoing frontline Acute Myeloid Leukemia (AML) triplet study (CA-4948-104) in a poster presentation at the 67th ASH Annual Meeting (ASH).